drugset / Trial / NCT05381181
Safety and Efficacy Evaluation of Next-generation CD19-UCART
Phase 1
Unknown
20 enrolled
Bioray Laboratories
The First Affiliated Hospital of Zhengzhou University · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of Next-generation CD19-UCART in patients with relapsed or refractory B-cell hematological malignancies.
Timeline
- Start
- 2023-12-20
- Primary completion
- 2024-05-30
- Completion
- 2026-05-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19-UCART | Cell therapy | 2e+06 cells/kg | — |
| Subject | CD19-UCART | Cell therapy | 5e+06 cells/kg | — |